Skip to content

MCG Post Myocardial Infarction Study

A Prospective Single-centre Pilot Study to Assess a Magnetocardiograph Device in Patients Following Myocardial Infarction.

Status
Completed
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT03358368
Enrollment
50
Registered
2017-11-30
Start date
2018-03-22
Completion date
2018-08-10
Last updated
2018-12-20

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Myocardial Infarction

Brief summary

The study is being performed to evaluate a new portable medical device, the Creavo Vitalscan Magnetocardiograph (Vitalscan) on patients who have had a confirmed myocardial infarction (heart attack) within the previous 12 weeks.

Detailed description

Magnetocardiography (MCG) is a non-contact, passive, imaging technique that detects the magnetic fields generated by the electrical activity of the heart. The MCG technology has been evaluated in several clinical studies, demonstrating its potential usefulness in the detection of patients with stable angina and acute coronary syndrome (ACS), including non-ST segment elevation myocardial infarction (NSTEMI). Previous studies have been completed using earlier versions of the Vitalscan device. Results showed that the device could differentiate between patients with confirmed ischaemic heart disease (IHD) and NSTEMI, those with non-IHD experiencing chest pain and healthy (non-ischaemic) control subjects. The aim of this pilot study is to assess the difference between abnormal MCG images from patients with a confirmed and recent myocardial infarction (MI)and normal images from previously obtained healthy volunteer controls scanned with the current device, so that comparisons can be made to the data acquired from the previous studies.

Interventions

DEVICEVitalscan

Vitalscan is a magnetocardiograph device

Sponsors

Creavo Medical Technologies Ltd
Lead SponsorINDUSTRY

Study design

Observational model
COHORT
Time perspective
PROSPECTIVE

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* Patients with confirmed myocardial infarction within 12 weeks of the initial event * Patients admitted to the Coronary Care Unit (CCU) at Warwick Hospital on the point of discharge or patients already discharged from the CCU attending the cardiac rehabilitation classes * 18+ year old male or female * Patient is willing and able to give written informed consent

Exclusion criteria

* Atrial fibrillation * Thoracic metal implants (cardiac stents allowed) * Pacemaker or internal defibrillator * Pregnancy (if after 20-week period)\* or lactation * Patient unable to lie down (i.e. supine position up to a maximum 25 degree tilt) or stay still on the examination bed * Patient unable to understand the informed consent process and/or has a poor understanding of English (e.g. English-speaking relative/translator not available) * There should not be any effect on pregnancy due to the non-invasive nature of the device. Pregnancy after the 20-week period excluded from the study due to the size and position of the foetus and unknown possibility of picking up the foetal heartbeat, rendering the scan non-usable for study requirements

Design outcomes

Primary

MeasureTime frameDescription
MCG parameter extractionFrom baseline scanTo extract parameters from MCG scans to identify key characteristics (markers) for myocardial infarction

Secondary

MeasureTime frameDescription
MCG parameter analysisFrom baseline scanTo use the markers identified to differentiate between abnormal (post MI) images and normal (healthy volunteer) images using evaluation performance measures

Countries

United Kingdom

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026